Day: January 5, 2019

Urovant Sciences Initiates Patient Enrollment in Phase 2a Clinical Trial for Vibegron in Patients with Abdominal Pain Due to Irritable Bowel Syndrome

From Startup Urovant Link to Full Article: BASEL, Switzerland & IRVINE, Calif.–(BUSINESS WIRE)–Jan. 3, 2019– Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, announced the company enrolled its first patient in a Phase 2a clinical trial evaluating vibegron in patients with